Menu
← Oncology Approval Tracker
FDA DECISION ·
Phyrago
dasatinib · Handa Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For children age 1 year or older with chronic-phase Philadelphia chromosome-positive CML or newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with chemotherapy.
LAMPGEN ANALYSIS
Why it matters
This approval extends the Phyrago product’s established dasatinib indications to eligible pediatric leukemia patients.
What research teams should watch
Align pediatric dosing and swallowing assessment with chemotherapy coordination and molecular response monitoring.
PRIMARY RECORDS